

**IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS**

This is an abridged prospectus containing salient features of the Prospectus. You are encouraged to read greater details available in the Prospectus available at [www.vilinbiomed.co.in](http://www.vilinbiomed.co.in).

THIS ABRIDGED PROSPECTUS CONTAINS EIGHT PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

**VILIN BIO MED LIMITED**

**Corporate Identification Number: U24230TG2005PLC046689; Date of Incorporation: June 29, 2005**

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
Sy.No.115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowempally, Secunderabad – 500003, Telangana, India	N.A.	Mr. Saket Kansal, Company Secretary and Compliance Officer	<b>E-mail:</b> <a href="mailto:cs@vilinbiomed.co.in">cs@vilinbiomed.co.in</a> <b>Tel:</b> +91 40 7961 8843	<a href="http://www.vilinbiomed.co.in">www.vilinbiomed.co.in</a>

**PROMOTERS OF OUR COMPANY: VISWA PRASAD SADHANALA, SADHANALA VENKATA RAO, D. SRINIVASA REDDY AND RAMESH REDDY SAMA**

DETAILS OF ISSUE TO PUBLIC			
Type	Fresh Issue Size	Total Issue Size	Eligibility
Fresh Issue	40,00,000 Equity Shares at the Issue Price of ₹ 30 each aggregating ₹ 1,200.00 Lakhs	40,00,000 Equity Shares at the Issue Price of ₹ 30 each aggregating ₹ 1,200.00 Lakhs	This Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended. The Issue is being made pursuant to Regulation 229 (2) of SEBI (ICDR) Regulations, as our Company's post issue paid up capital is more than ₹ 10.00 Cr.

These Equity Shares are proposed to be listed on the SME Platform of National Stock Exchange of India Limited ("NSE"). For the purposes of this Issue, NSE is the Designated Stock Exchange.

ISSUE PRICE, MINIMUM APPLICATION LOT AND INDICATIVE TIMELINES			
The below dates are indicative. However actual dates may vary.			
<b>Issue Price</b>	₹ 30 per Equity Share	<b>Minimum Lot Size</b>	4,000 Equity Shares
<b>Issue Opening Date</b>	June 16, 2023	<b>Initiation of Unblocking of funds / Refund</b>	June 27, 2023
<b>Issue Closing Date</b>	June 21, 2023	<b>Credit of Equity Shares to demat accounts of Allottees</b>	June 29, 2023
<b>Finalization of basis of allotment with the Designated Stock Exchange</b>	June 26, 2023	<b>Commencement of trading of Equity Shares on the Stock Exchanges</b>	June 30, 2023

\*For details of price and basis of issue price, please refer to page 66 of Prospectus.

**Details of WACA of all shares transacted over the trailing eighteen months from the date of Prospectus:**

Period	Weighted Average Cost of Acquisition (in ₹)	Issue Price is 'X' times the WACA	Range of acquisition Price Lowest Price - Highest Price (in ₹)
Trailing Eighteen Month from the date of the Prospectus	₹ 3.07	9.78	₹ Nil to ₹ 30

WACA: Weighted Average Cost of Acquisition has been calculated on fully diluted basis for the trailing eighteen months from the date of prospectus.

RISKS IN RELATION TO FIRST ISSUE
This being the first Public Issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ₹ 10/- each and the Issue Price of ₹ 30 is 3.00 times of the face value of the Equity Shares. The Issue Price (determined and justified by our Company in consultation with the Lead Manager) as stated under "Basis for Issue Price" beginning on page no. 66 of the Prospectus should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 16.

## PROCEDURE

You may obtain a physical copy of the Application Form and the Prospectus from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stockbrokers, underwriters, bankers to the issue, investors' associations or Self Certified Syndicate Banks.

If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the Prospectus and/or the General Information Document (GID) from the Lead Manager or download it from the websites of the Stock Exchanges i.e. [www.nseindia.com](http://www.nseindia.com); and the Lead Manager i.e. [www.inventuremerchantbanker.com](http://www.inventuremerchantbanker.com).

## PRICE INFORMATION OF LEAD MANAGER – INVENTURE MERCHANT BANKER SERVICES PRIVATE LIMITED

Sr. No.	Issue Name	+/- % change in closing price, [ $\pm$ % change in closing benchmark]- 30th calendar days from listing	+/- % change in closing price, [ $\pm$ % change in closing benchmark]- 90th calendar days from listing	+/- % change in closing price, [ $\pm$ % change in closing benchmark]-180th calendar days from listing
1.	Navoday Enterprises Limited	-27.50% (-0.10%)	-38.05% (13.15%)	-47.50% (7.57%)
2.	AA Plus Tradelink Limited	-50.00% (4.72%)	-59.72% (15.94%)	-51.94% (14.98%)
3.	Omnipotent Industries Limited	-38.81% (0.95%)	-49.21% (-2.45%)	-63.57 (-4.15)
4.	Brandbucket Media & Technology Limited	-38.73% (-1.81%)	-66.18% (0.54%)	-74.36% (-8.97%)
5.	Silver Pearl Hospitality & Luxury Spaces Limited	-37.56% (4.67)	-49.22% (16.69%)	-56.11 (22.04%)
6.	Maagh Advertising And Marketing Services Limited	-21.80% (7.97%)	-43.90% (5.01%)	68.73% (5.11%)

source: [www.bseindia.com](http://www.bseindia.com)

Note:-

1. The BSE Sensex and Nifty are considered as the Benchmark Index
2. Prices on BSE/NSE are considered for all of the above calculations
3. In case the 30th/90th/180th day is a holiday, closing price on BSE/NSE of the previous trading day has been considered.
4. In case 30th/90th/180th days, scrips are not traded then closing price on BSE/NSE of the previous trading day has been considered.

Name of BRLM and contact details (telephone and email id) of each BRLM	<b>Inventure Merchant Banker Services Private Limited</b> 2 <sup>nd</sup> Floor, Viraj Tower, Nr. Andheri Flyover (North End), Western Express Highway, Andheri (East) Mumbai – 400 069, Maharashtra <b>Tel No:</b> +91 22 4075 1500 <b>Fax No:</b> +91 22 4075 1511 <b>Email:</b> <a href="mailto:compliance@inventuremerchantbanker.com">compliance@inventuremerchantbanker.com</a> <b>Investor Grievance Email:</b> <a href="mailto:redressal@inventuremerchantbanker.com">redressal@inventuremerchantbanker.com</a> <b>Website:</b> <a href="http://www.inventuremerchantbanker.com">www.inventuremerchantbanker.com</a> <b>SEBI Registration No:</b> INM000012003 <b>Contact Person:</b> Arvind Gala
Name of Registrar to the Issue and contact details (telephone and email id)	<b>BIGSHARE SERVICES PRIVATE LIMITED</b> <b>Tel. No.:</b> +91 22 6263 8200 <b>Email:</b> <a href="mailto:ipo@bigshareonline.com">ipo@bigshareonline.com</a> <b>Website:</b> <a href="http://www.bigshareonline.com">www.bigshareonline.com</a> <b>Investor Grievance Email:</b> <a href="mailto:investor@bigshareonline.com">investor@bigshareonline.com</a>
Name of Market Maker	<b>RIKHAV SECURITIES LIMITED</b> 34/35/36/38, Matruchhaya, 4th Floor, Sarojini Naidu Road, Mulund West Mumbai-400080, Maharashtra, India. <b>Tel No.:</b> +91 22 6907 8300 <b>Email:</b> <a href="mailto:info@rikhav.net">info@rikhav.net</a> <b>Website:</b> <a href="http://www.rikhav.net">www.rikhav.net</a> <b>SEBI Registration No:</b> INZ000157737 <b>Contact Person:</b> Hitesh Himmatlal Lakhani
Name of Statutory Auditor	<b>M/s. PPKG &amp; Co., Chartered Accountants, Hyderabad</b>
Name of Credit Rating Agency and the rating or grading obtained, if any	NA

Name of Debenture trustee, if any	NA
Self Certified Syndicate Banks	The list of banks is available on <a href="https://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Intermediaries">https://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Intermediaries</a>
Non Syndicate Registered Brokers	You can submit Application Forms in the Issue to Non Syndicate Registered Brokers at the Non Syndicate Broker Centres . For further details, see section titled “Issue Procedure” beginning at page 180 of the Prospectus
Details regarding website address(es)/link(s) from which the investor can obtain list of registrar to issue and share transfer agents depository participants and stock brokers who can accept application from investor (as applicable)	The details of the Designated Registrar and Share Transfer Agents Locations and Designated Collecting Depository Participant Locations, along with their names and contact details are available on the websites of the Stock Exchange <a href="http://www.nseindia.com">www.nseindia.com</a> and updated from time to time.

#### PROMOTERS OF THE ISSUER COMPANY

Sr. No.	Name	Individual / Corporate	Experience & Educational Qualification
1	Viswa Prasad Sadhanala	Individual	<p><b>Viswa Prasad Sadhanala</b>, aged 57 years, is the Managing Director of our Company. He has completed his B.Com, M.Com and LLb from Andhra University. He has also completed his MBA Marketing from Andhra University. He served for 15 years in Indian Navy. He is also having over a decade of experience in the field of HR and office administration. He is also one of the Promoters of our Company. He looks after the legal and administration aspects of our business on day to day basis.</p> <p><b>Educational Qualification:</b> B.Com, M.Com and LLb from Andhra University</p>
2.	Ramesh Reddy Sama	Individual	<p><b>Ramesh Reddy Sama</b>, aged 50 years, is one of the Promoters of our Company. He has completed his Bachelor of Pharmacy from Marathwada University. He is having over two decades of experience in Pharma Industry. He was previously working various pharma companies and is also having his proprietary business of pharma trading. He provides strategic guidance to our Company and also takes care of plant operations.</p> <p><b>Educational Qualification:</b> Bachelor of Pharmacy from Marathwada University</p>
3.	Sadhanala Venkata Rao	Individual	<p><b>Sadhanala Venkata Rao</b>, aged 59 years, is one of the Promoters of our Company. He is a qualified Chartered Accountant and Company Secretary. having more than 3 decades of experience in handling a diverse team of Finance, Legal and Secretarial and Managing finance effectively, Legal Compliance, Corporate Governance, Regulation Affairs, Mergers &amp; Acquisitions, Public Issues, Private equity deals contract/litigation management and company secretarial function. He was previously worked with various corporates and also work as independent corporate and financial consultant. He provides strategic guidance to our Company with respect to funding and other financial aspects of our business.</p> <p><b>Educational Qualification:</b> Chartered Accountant</p>
4.	D. Srinivasa Reddy	Individual	<p><b>D. Srinivasa Reddy</b>, aged 40 years, is one of the Promoters of our Company. He is a qualified Chartered Accountant. having more than a decade of experience in banking, accounts and finance. He provides looks into accounting aspects of our business, provides requisite guidance to the accounting team.</p> <p><b>Educational Qualification:</b> Chartered Accountant</p>

#### BUSINESS OVERVIEW AND STRATEGY

##### Company Overview:

Our Company is engaged in domestic business of manufacturing Pharmaceuticals products and the Manufacturing Unit is located in Roorkee, in the State of Uttarakhand. In order to maintain our competitiveness and to further the cause of Healthcare, our Company has laid a R&D Foundation and state of the art Manufacturing Facility in Roorkee. Our Sales Strategy is to sell our products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders, who in turn provide the channel for sales to customers. Our products are primarily used by other pharmaceutical companies and traders, who ultimately will market it to the distributors and retail customers. We do not sell our products under any brand name. Following are our major products (manufacturing dosage forms):

- Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non βeta-Lactam)
- Tablets & Capsules (βeta & Non βeta-Lactam).
- External Preparations

Our Promoters, Mr. Sadhanala Venkata Rao, Mr. Viswa Prasad Sadhanala, Mr. D. Srinivasa Reddy, and Mr. Anuj Bajpai, Executive Director are actively involved in the day-to-day business. Our Promoters are the guiding force behind the Strategic Decisions of our Company. Their Industry Knowledge and understanding of the current market situation enables us to improve our geographic horizon and market presence.

## **Product /Service Offering:**

### **Our Product Profile**

Our products can be classified in following categories:

- a. Solid Oral Dosage form (βeta & Non βeta-Lactam).
- b. Oral Liquids.
- c. External Preparations.
- d. Dry Powders

### **Our major products include the following:**

- Cefixime-200mg+Lactic Acid Bacillus -60ms
- Cefixime -200mg+Ofloxacin-200mg+Lactic Acid Bacillus- 60ms
- Azithromycin -250/500mg+Lactic Acid Bacillus -60ms
- Sulmtmicilline-375mg
- Aceclofenac-100mg+Paracetamol -325mg+serratiopeptidase -15mg
- Citicolin Sodium-500mg+Piracetam-800mg
- Metformine -500/1000mg+Glimepride-1/2/3/4mg+Voglibose -0.2mg/0.3mg
- Pregabalin -75mg+Nortriptyline -10mg+Methylcobalamine -1500mcg
- Gabapentin -300mg+Methylcobalamine -500mcg
- Diclofenac Sodium -1%w/w
- Thiocolchicoside -0.125%w/w
- Linseed oil-3%w/w
- Menthol -5%w/w
- Methyl salicylate-10%w/w

### **Our locational presence:**

**Registered Office:** Sy. No. 115, Opposite Sub - Registrar's Office, Hanumanji Colony, Old Bowenpally, Secunderabad - 500003, Telangana, India

**Manufacturing Unit:** Kasara.No. 85, Madhopur, Hazratpur, Roorkee, Haridwar, Uttarakhand, India

**Revenue segmentation by geographies and Products segmentation:** Please refer page 80 of the Prospectus.

### **Key Performance Indicators:**

#### **1. Key Operational And Financial Performance Indicators:**

The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analyzing the growth of various verticals in comparison to our peers.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated June 7, 2023 and the members of the Audit Committee have verified the details of all KPIs pertaining to our Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three-year period prior to the date of filing of this Prospectus. Further, the KPIs herein have been certified by M/s. PPKG & Co., Chartered Accountants, Chartered Accountants, by their certificate dated June 7, 2023.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilisation of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Issue Section, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

## Financial KPIs of our Company

(₹ in lakhs, except for percentage)

Particulars	For nine months period ended December 31, 2022	Fiscal 2022	Fiscal 2021	Fiscal 2020
Revenue from operations	901.29	1,121.49	1,171.52	1,681.29
Total Income	903.43	1,121.91	1,171.88	1,682.41
EBITDA <sup>(1)</sup>	235.52	77.01	86.02	91.05
EBITDA margin (%) <sup>(2)</sup>	26.07%	6.86%	7.34%	5.41%
PAT	128.08	3.35	12.13	16.22
PAT Margin (%)	14.18%	0.30%	1.03%	0.96%
Net Debt <sup>(3)</sup>	614.16	526.06	546.93	446.75
Total Equity/Net Worth	867.69	739.61	736.26	724.13
ROE (%) <sup>(4)</sup>	14.76%	0.45%	1.65%	2.24%
ROCE (%) <sup>(5)</sup>	8.58%	0.26%	0.94%	1.37%
EPS (Basic & Diluted) <sup>(6)</sup>	1.55	0.04	0.15	0.20

<sup>(1)</sup>EBITDA = Profit before tax + depreciation & amortization expense + finance cost.

<sup>(2)</sup>EBITDA Margin = EBITDA/ Total income.

<sup>(3)</sup>Net debt = Non-current borrowing + current borrowing - Cash and Cash Equivalent, Bank Balance, and Investment in Mutual Funds.

<sup>(4)</sup>ROE = Net profit after tax /Total equity.

<sup>(5)</sup>ROCE = Profit before tax and finance cost / Capital employed\*

\*Capital employed = Total Equity +Non-current borrowing + current Borrowing + Deferred Tax Liabilities – Intangible Assets

<sup>(6)</sup>EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of equity shares outstanding during the year/ period.

For further details please refer to page 67 of the Prospectus.

### Client Profile or Industries Served: Revenue segmentation in terms of top 5/10 clients or Industries:

Our Sales Strategy is to sell our products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders, who in turn provide the channel for sales to customers.

Particulars	Financial Year ended December 31, 2022	Financial Year ended March 31, 2022
Customers' contribution Top 10 (%)	96.23	82.51

### Intellectual Property:

For details please refer page 94 of the Prospectus.

### Market Share: Not Ascertainable

**Manufacturing plant, if any:** Manufacturing Unit: Kasara.No. 85, Madhopur, Hazratpur, Roorkee, Haridwar, Uttarakhand, IndiaFor further details of ownership / lease of the above units, please refer to “Our Business” on page 94 of the Prospectus.

**Employee Strength:** As on the date of the Prospectus, we have 61 employees and Nil contractual employees.

For further details, please refer chapter titled ‘Business Overview’ on page 80 of the Prospectus.

## BOARD OF DIRECTORS

Sr. No.	Name	Designation	Experience & Educational Qualification	Other Directorships
1.	<b>Veerareddy Vallapureddy</b>	Non-Executive Chairman and Independent Director	aged 55 years, is the Non-Executive Chairman and Independent Director of our Company. He has completed his Bachelor of Commerce from Acharya Nagarjuna University. He has also completed his B.Ed from Annamalai University. He is having over a two decades of experience in the field of administration, legal and marketing. of marketing and exhibitions. He provides strategic guidance to our Company. He has been on our Board since January 4, 2023.	Indian Companies: Nil Foreign Companies: Nil LLPs: <ul style="list-style-type: none"> <li>Sunaxa Pharma LLP</li> <li>Winx Media And PR LLP</li> </ul>
2.	<b>Viswa Prasad Sadhanala</b>	Managing Director	aged 57 years, is the Managing Director of our Company. He has completed his B.Com, M.Com and LLb from Andhra University. He has also completed his MBA Marketing from Andhra University. He served for 15 years in Indian Navy. He is also having over a decade of experience in the field of HR and office administration. He is also one of the Promoters of our Company. He looks after the legal and administration aspects of our business on day to day basis.	Indian Companies: Nil Foreign Companies: Nil
3.	<b>Anuj Bajpai</b>	Executive Director	aged 45 years, is an Executive Director of our Company. He has completed his B.Sc from Shri Shahu Ji Maharaj University, Kanpur. He is having experience of over 20 years in the pharma industry including in sales and marketing of pharma products which involved interacting with customers for sourcing the orders and supply of the materials. He takes care of plant operations and other technical aspects of our business.	Indian Companies: <ul style="list-style-type: none"> <li>Redizen Lifesciences Private Limited</li> <li>Spectrogen International Private Limited</li> </ul> Foreign Companies: Nil
4.	<b>Padmaja Kalyani Sadhanala</b>	Non- Executive Director	aged 51 years, is the non-executive Director of our Company. She has completed her M.Sc (Zoology), Cell Biology & Genetics and has also completed Post-Graduate Diploma in Protein Modelling and Rational Drug Designing. She has more than 20 years of experience in the Pharma Industry.	Indian Companies: Blue Nile Capital Advisory Limited Foreign Companies: Nil
5	<b>Rakesh Kumar Chandak</b>	Independent Non-Executive Director	aged 34 years, is an Independent Director of our Company. He has completed his B.Com from Andhra University. He is also an associate of the Institute of Company Secretaries of India. He is having experience of over 10 years in finance and legal fields. He has been on our Board since January 4, 2023.	Indian Companies: Nil Foreign Companies: Nil

For further details, please refer chapter titled “Our Management” on page no. 101 of the Prospectus.

## OBJECTS OF THE ISSUE

The objects of the Net Proceeds of the Issue are:

1. Augmenting additional working capital requirements
2. General Corporate Purposes

### Details of means of finance:

Since the entire fund requirement are to be funded from the proceeds of the Issue, there is no requirement to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance, excluding the amounts to be raised through the proposed Issue.

The find requirements for each of the objects of the Issue are stated as follows:

(₹ in Lakhs)

Sr. No.	Particulars	Expenses Already Incurred till June 5, 2023	FY 2023-24	Total
1	Augmenting additional working capital requirements	0.00	848.89	848.89
2	General Corporate Purposes	0.00	251.11	251.11
3	Issue Related Expenses	20.91	79.09	100.00
	<b>Total</b>	<b>20.91</b>	<b>1,179.09</b>	<b>1,200.00</b>



**Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues/rights issues, if any, of the Company in the preceding 10 years:** Not Applicable

**Name of monitoring agency, if any:** Not Applicable

**Terms of Issuance of Convertible Security, if any:** Not Applicable

SHAREHOLDING PATTERN		
Particulars	Pre-Issue	
	No. of Shares	% Holding
Promoters and Promoter Group	90,00,000	90.45
Public	9,50,000	9.55
Non Promoter Non Public	Nil	Nil
<b>Total</b>	<b>99,50,000</b>	<b>100.00</b>

**Number/amount of equity shares proposed to be sold by selling shareholders, if any:** Not Applicable

RESTATED AUDITED FINANCIAL STATEMENTS (CONSOLIDATED)				
Particulars	31.03.22	31.03.22	31.03.21	31.03.20
Total income from operations (Net)	903.43	1,121.91	1,171.88	1,682.41
Net Profit / (Loss) before tax and extraordinary items	174.44	4.46	16.11	19.38
Net Profit / (Loss) after tax and extraordinary items	174.44	4.46	16.11	19.38
Equity Share Capital	330.00	330.00	330.00	330.00
Reserves & Surplus (after revaluation reserves)	537.69	409.61	406.26	394.13
Net worth	867.69	739.61	736.26	724.13
Basic and Diluted Earnings per Equity Share (Considering bonus in all previous years in the ratio of 1.50:1)	1.55	0.04	0.15	0.20
Return on net worth (%)	14.76%	0.45%	1.65%	2.24%
Net Asset Value/Book Value per Equity share (Considering bonus in all previous years in the ration of 1.50:1)	10.52	8.96	8.92	8.78

For further details on Financial Information, please refer chapter titled “Financial Statements as Restated” on page no. 121 of the Prospectus.

#### INTERNAL RISK FACTORS

Below mentioned risks are the top 10 risk factors as per the Prospectus:

1. There are certain outstanding legal proceeding against our company which may adversely affect our business, financial condition and results of operations.
2. There are outstanding criminal legal proceedings involving our Company which may adversely affect our business, financial condition and results of operations.
3. There were certain NCLT cases that have been filed against our Company in the past.
4. We conduct our business activities on a purchase order basis and therefore have not entered into long-term agreements with our customers.
5. Our Company is reliant on the demand from the pharmaceutical industry for a significant portion of our revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage our sales could have an adverse impact on our Company's business and results of operations.
6. We highly depend on our major raw materials and a few key suppliers who help us procure the same. Our Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event we are unable to procure adequate amounts of raw materials, at competitive prices our business, results of operations and financial condition may be adversely affected.
7. Our continued operations are critical to our business and any shutdown of our manufacturing unit may adversely affect our business, results of operations and financial condition.
8. Any failure in our quality control processes may adversely affect our business, results of operations and financial condition. We may face product liability claims and legal proceedings if the quality of our products does not meet our customers' expectations.
9. Any adverse change in regulations governing our products and the products of our customers, may adversely impact our business prospects and results of operations.
10. Any delays and/or defaults in customer payments could result in increase of working capital investment and/or reduction of our Company's profits, thereby affecting our operation and financial condition.

For further details, please refer chapter titled ‘Risk Factors’ on page 16 of the Prospectus.

## SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

### A. Total Number of Outstanding Litigations Against the Company, Director, Promoters, Subsidiaries and the Amount Involved

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount involved (Rs in Lakhs)
<b>Company</b>						
By the Company	Nil	Nil	Nil	Nil	Nil	Nil
Against the Company	6	8	Nil	Nil	Nil	63.90
<b>Directors</b>						
By the Directors	Nil	Nil	Nil	Nil	Nil	Nil
Against the Directors	Nil	Nil	Nil	Nil	Nil	Nil
<b>Promoters</b>						
By the Promoters	Nil	Nil	Nil	Nil	Nil	Nil
Against the Promoters	Nil	Nil	Nil	Nil	Nil	Nil
<b>Subsidiaries and Group Entities</b>						
By Subsidiaries and Group Entities	Nil	Nil	Nil	Nil	Nil	Nil
Against Subsidiaries and Group Entities	Nil	Nil	Nil	Nil	Nil	Nil

### B. Brief details of top 5 material outstanding litigations against the company and amount involved: Not Applicable

Sr. No	Petitioner Name	Brief fact of the case	Subject matter	Amount	Current Status
1.	State at the Instance of Assistant Drugs Controller	Assay Variation in the sample drug of "sodium feredetate" between the State of the Instance of Assistant Drugs Controller 1 and the Company	Variation in the sample drug of "sodium feredetate"	--	The case has been Filed by the Assistant drug controller, Dharwad against the Company regarding Assay variation, and the hearing is fixed on 07.06.2023
2	Bansal Enterprises	₹ 443381/- is the dispute amount for supply of raw materials to the company	Payment default in the supply of raw material	₹ 443381/-	Hearing is fixed on next hearing date 17.10.2023
3	M/S Amit Pharma Chem UK	₹2726276/- is the dispute amount for supply of raw materials to the company	Payment default in the supply of raw material	₹ 2726276	Hearing is fixed on next hearing date is 13.09.2023
4	M/S Aay Cee Enterprises	₹590165/- is the dispute amount for supply of raw materials to the company	Payment default in the supply of raw material	₹ 590165	Hearing is fixed on next hearing date is 13.09.2023
5	Sonex	dispute amount for supply of raw materials to the company	Payment default in the supply of raw material	₹ 6,51,640	The Case was settled through NCLT on 01.04.2022. Copy of NCLT enclosed.
6	Ravinder Gupta	₹ 88,000/- is the dispute amount for supply of packaging materials to the company	Payment default in the supply of packaging material	₹ 88,000	Next date of hearing is next hearing date is 27.07.2023

### C. Regulatory Action, if any- disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: Not Applicable

### D. Brief details of outstanding criminal proceedings against Promoters: Not Applicable

**ANY OTHER IMPORTANT INFORMATION AS PER LEAD MANAGER / ISSUER COMPANY: NOT APPLICABLE**

### DECLARATION BY THE COMPANY

We, hereby declare that all the relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Prospectus is contrary to the provisions of the Companies Act, 2013 the Securities and Exchange Board of India Act, 1992 or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements are true and correct.